Increased CD68 in tumor bulk (p < 0.01) and infiltrative regions (p = 0.02). Increased CD11b+ in tumor bulk (p < 0.01) and trend increase in I filtrate region (p = 0.09). Increased CD163 in tumor bulk (p = 0.09) in therapy group. Sequencing validated by IHC. Here, CD163 is linked to neoplasm.